{"id":"W2912107322","doi":"10.1016/j.jtho.2019.02.001","title":"Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M–Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":210,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Daiichi Sankyo Company; Astellas Pharma Canada; Meso Scale Diagnostics; AbbVie; Takeda Pharmaceuticals North America; EMD Serono; Novartis; Bayer; Celgene; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Pfizer","keywords":"Osimertinib; Medicine; Durvalumab; T790M; Oncology; Internal medicine; Epidermal growth factor receptor; Cancer; Gefitinib; Erlotinib; Nivolumab","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000847291,0.0003073859,0.001139908,0.0003331922,0.0000898646,0.00003103613,0.0001959802,0.0002680008,0.0002687468],"category_scores_gemma":[0.0001659646,0.0002384967,0.0005130347,0.0003550413,0.00007096183,0.0003082271,0.00003512459,0.0006147041,0.00003925365],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001947548,"about_ca_system_score_gemma":0.001917464,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002858063,"about_ca_topic_score_gemma":0.00005694566,"domain_scores_codex":[0.9971683,0.0002976987,0.001207188,0.000368869,0.0004891412,0.0004688163],"domain_scores_gemma":[0.9976627,0.0003802855,0.001047031,0.0003854506,0.000290805,0.0002336963],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.08856335,0.004952964,0.1575893,0.0001688629,0.009899967,0.03004933,0.02254404,0.0008399034,0.01651844,0.0001154668,0.003325646,0.6654328],"study_design_scores_gemma":[0.1897545,0.05663578,0.4567123,0.003496486,0.006923649,0.02032645,0.007931989,0.001042447,0.01990306,0.000706819,0.2344354,0.002131067],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9774047,0.004739496,0.0001016312,0.005015175,0.002750525,0.001041217,0.000006525046,0.00003055469,0.008910152],"genre_scores_gemma":[0.9944422,0.0004985453,0.001546929,0.001117875,0.0004583777,0.00003471113,0.00002688718,0.00006067269,0.001813853],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6633016,"threshold_uncertainty_score":0.9725612,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02743526154477344,"score_gpt":0.4405778436775608,"score_spread":0.4131425821327874,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}